July 15, 2014
2 min read

Dengue vaccine efficacious in phase 3 trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Sanofi Pasteur’s investigational quadrivalent dengue vaccine demonstrated an overall efficacy of 56.5% and led to an 88.5% reduction of severe disease among children, according to the results of a phase 3 trial published in The Lancet.

“The results of this first phase 3 study show the potential of the vaccine to have a significant impact on public health,” study researcher Maria Rosario Capeding, MD, of the Research Institute for Tropical Medicine in the Philippines, said in a press release. “The threat of severe dengue disease creates fear in the community. The vaccine’s impact on preventing dengue hemorrhagic fever is noteworthy. A vaccine that is able to avoid the personal suffering and reduce this significant health burden would change the lives of millions.”

The randomized clinical trial included 10,275 children aged 2 to 14 years in five countries across the Asian-Pacific region, including Indonesia, Malaysia, Thailand, Vietnam and the Philippines. Children received three injections of a recombinant, live-attenuated, quadrivalent dengue vaccine (CYD-TDV) or placebo at 0, 6 and 12 months. Participants were followed up for 25 months.

Results indicated that 250 cases of virologically confirmed dengue infection took place more than 28 days after the third injection — 117 (47%) children who received the vaccine and 133 (53%) in the control group. The vaccine reduced up to 56.5% (95% CI, 43.8-66.4) of cases, and its efficacy was higher in children with pre-existing dengue neutralizing antibodies.

Secondary analyses suggested that all four dengue serotypes contributed to the vaccine’s overall efficacy.

After three injections, vaccine efficacy against hemorrhagic fever was 88.5% (95% CI, 58.2-97.9). The vaccine also reduced hospital admissions by 67.2% (95% CI, 50.3-78.6).

The safety profile of CYD-TDV was favorable, according to the researchers. A total of 647 serious adverse events were recorded; 402 (62%) in the vaccine group and 245 (38%) in the control group. Serious adverse events were consistent with medical disorders typical for this age group and resulted primarily from infections and injuries, the researchers said.

The study revealed a significantly higher burden of disease than previously expected — up to three times higher, with an estimated one in 20 children in the control group affected by dengue each year.

“This trial was successfully done over more than 2 years in diverse dengue-endemic areas in Asia, a region that accounts for 70% of the global dengue burden,” the researchers wrote. “In this setting, we recorded promising results pointing to a substantial effect on severe disease manifestations. The safety and efficacy profile described here suggests that the CYD-TDV vaccine candidate, when given as three injections at months 0, 6, and 12 to 2-14 year-olds, has the potential to provide an important public health benefit in dengue-endemic countries.”

Disclosure: The study was funded by Sanofi Pasteur.